Check with:
Ventana Medical Systems, S.A.
Parc d'Innovation, BP 30144
Rue G. de Kaysersberg
67404 ILLKIRCH CEDEX
France
Tel. +011 33 390 40 5200
Fax  +011 33 390 40 5240

Hope this helps,

Juan C. Gutierrez, HT(ASCP)
Histology Supervisor
Christus Santa Rosa Hospital
(210)704-2533
Juan_Gutierrez@srhc.iwhs.org


-----Original Message-----
From: Frouwke Kuijpers [mailto:frouwke@sci.kun.nl]
Sent: Thursday, July 10, 2003 3:27 AM
To: Histonet (E-mail); Sebree Linda A.
Cc: histonet
Subject: Re: New I-View kit for IHC


Where can I find that iview DAB? Is it also delivered in Europe?

Frouwke Kuijpers

F.J.Kuijpers-Kwant
Dept. Cellular Animal Physiology
University of Nijmegen
Toernooiveld 1
6525 ED Nijmegen
the Netherlands
frouwke@sci.kun.nl

----- Original Message ----- 
From: "Sebree Linda A." 
To: "Chung, Luong" ; "Histonet (E-mail)"

Sent: Wednesday, July 09, 2003 9:50 PM
Subject: RE: New I-View kit for IHC


> I'll assume you are talking about iview DAB.  We have found that it
results in a very clean and somewhat more intense staining product (than
Basic DAB).  In some instances we've been able to reduce or eliminate HIER
or remove amplification from our protocol.
>
> Linda A. Sebree, HT(ASCP)
> University of Wisconsin Hospital & Clinics
> IHC/ISH Laboratory
> A4/204-2472
> 600 Highland Ave.
> Madison, WI 53792
> (608)265-6596
> FAX: (608)262-7174
>
>
> -----Original Message-----
> From: Chung, Luong [mailto:lchung@ppmh.org]
> Sent: Wednesday, July 09, 2003 2:32 PM
> To: Histonet (E-mail)
> Subject: New I-View kit for IHC
>
>
> All
>
> Has anyone experience with the new I-view kit for IHC (ventana-nexus)?
How
> is it?  We in the process of changing over to it.
>
> Any suggestion would be very helpful.
>
> Thanks
>
>
>
> HIPAA Privacy Rule requires covered entities to safeguard certain
Protected
> Health Information (PHI) related to a person's healthcare. Information
being
> sent to you may include PHI, after appropriate consent, acknowledgement,
or
> authorization from the patient or under circumstances that do not require
> patient authorization. You, the recipient, are obligated to maintain PHI
in
> a safe and secure manner. You may not re-disclose this patient information
> without additional patient consent or as required by law. Unauthorized
> re-disclosure or failure to safeguard PHI could subject us, or you, to
> penalties described in federal (HIPAA) and state law. If you, the reader
of
> this message, are not the intended recipient, or the employee or agent
> responsible to deliver it to the intended recipient, please notify us
> immediately and destroy the related message. Thanks for your help.
>
>